靶向ANGPTL3的sirna治疗混合性血脂异常。

IF 12.8 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Med Pub Date : 2025-06-13 DOI:10.1016/j.medj.2025.100746

Ioanna Gouni-Berthold

{"title":"靶向ANGPTL3的sirna治疗混合性血脂异常。","authors":"Ioanna Gouni-Berthold","doi":"10.1016/j.medj.2025.100746","DOIUrl":null,"url":null,"abstract":"The PROLONG-ANG3 trial demonstrated that two doses of solbinsiran, an siRNA targeting hepatic ANGPTL3, given 90 days apart, decreased concentrations of apoB, triglycerides, LDL-C, non-HDL-C, ANGPTL3, and hepatic fat content at day 180 in adults with mixed dyslipidemia.1 Long-term studies assessing the safety of solbinsiran and its efficacy in decreasing the risk of atherosclerotic cardiovascular disease are warranted.","PeriodicalId":29964,"journal":{"name":"Med","volume":"6 6","pages":"100746"},"PeriodicalIF":12.8000,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"siRNAs targeting ANGPTL3 for mixed dyslipidemia.\",\"authors\":\"Ioanna Gouni-Berthold\",\"doi\":\"10.1016/j.medj.2025.100746\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The PROLONG-ANG3 trial demonstrated that two doses of solbinsiran, an siRNA targeting hepatic ANGPTL3, given 90 days apart, decreased concentrations of apoB, triglycerides, LDL-C, non-HDL-C, ANGPTL3, and hepatic fat content at day 180 in adults with mixed dyslipidemia.1 Long-term studies assessing the safety of solbinsiran and its efficacy in decreasing the risk of atherosclerotic cardiovascular disease are warranted.\",\"PeriodicalId\":29964,\"journal\":{\"name\":\"Med\",\"volume\":\"6 6\",\"pages\":\"100746\"},\"PeriodicalIF\":12.8000,\"publicationDate\":\"2025-06-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Med\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.medj.2025.100746\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Med","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.medj.2025.100746","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

摘要

PROLONG-ANG3试验表明，两种剂量的solbinsiran，一种靶向肝脏ANGPTL3的siRNA，间隔90天，在180天降低了混合性血脂异常成人的载脂蛋白ob、甘油三酯、LDL-C、非hdl - c、ANGPTL3的浓度和肝脏脂肪含量评估索宾西兰的安全性及其降低动脉粥样硬化性心血管疾病风险的有效性的长期研究是有必要的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

siRNAs targeting ANGPTL3 for mixed dyslipidemia.

The PROLONG-ANG3 trial demonstrated that two doses of solbinsiran, an siRNA targeting hepatic ANGPTL3, given 90 days apart, decreased concentrations of apoB, triglycerides, LDL-C, non-HDL-C, ANGPTL3, and hepatic fat content at day 180 in adults with mixed dyslipidemia.¹ Long-term studies assessing the safety of solbinsiran and its efficacy in decreasing the risk of atherosclerotic cardiovascular disease are warranted.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Med MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

17.70

自引率

0.60%

发文量

102

期刊介绍： Med is a flagship medical journal published monthly by Cell Press, the global publisher of trusted and authoritative science journals including Cell, Cancer Cell, and Cell Reports Medicine. Our mission is to advance clinical research and practice by providing a communication forum for the publication of clinical trial results, innovative observations from longitudinal cohorts, and pioneering discoveries about disease mechanisms. The journal also encourages thought-leadership discussions among biomedical researchers, physicians, and other health scientists and stakeholders. Our goal is to improve health worldwide sustainably and ethically. Med publishes rigorously vetted original research and cutting-edge review and perspective articles on critical health issues globally and regionally. Our research section covers clinical case reports, first-in-human studies, large-scale clinical trials, population-based studies, as well as translational research work with the potential to change the course of medical research and improve clinical practice.